Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

被引：0
|
作者：
Shinsuke Sasada
Naoto Kondo
Hiroya Hashimoto
Yuko Takahashi
Kaori Terata
Kumiko Kida
Yasuaki Sagara
Takayuki Ueno
Keisei Anan
Akihiko Suto
Chizuko Kanbayashi
Mina Takahashi
Rikiya Nakamura
Toshiyuki Ishiba
Michiko Tsuneizumi
Seiichiro Nishimura
Yoichi Naito
Fumikata Hara
Tadahiko Shien
Hiroji Iwata
机构：
[1] Hiroshima University,Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine
[2] Nagoya City University Graduate School of Medical Sciences,Department of Breast Surgery
[3] Nagoya City University Graduate School of Medical Sciences,Core Laboratory
[4] Okayama University Hospital,Department of Breast and Endocrine Surgery
[5] Akita University Hospital,Department of Breast and Endocrine Surgery
[6] St. Luke’s International Hospital,Department of Breast Surgical Oncology
[7] Social medical corporation Hakuaikai,Department of Breast and Thyroid Surgical Oncology
[8] Sagara Hospital,Breast Oncology Center
[9] The Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[10] Kitakyushu Municipal Medical Center,Department of Breast Surgery
[11] National Cancer Center Hospital,Department of Breast Oncology
[12] Niigata Cancer Center Hospital,Department of Breast Oncology
[13] National Hospital Organization Shikoku Cancer Center,Department of Breast Surgery
[14] Chiba Cancer Center,Department of Breast Surgery
[15] Tokyo Metropolitan Cancer and Infectious Diseases Center,Department of Breast Surgery
[16] Komagome Hospital,Department of Breast Surgery
[17] Shizuoka General Hospital,Department of General Internal Medicine
[18] Shizuoka Cancer Center Hospital,Department of Breast Oncology
[19] National Cancer Center Hospital East,undefined
[20] Aichi Cancer Center Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2023年 / 202卷
关键词：
Breast cancer; T1a/b; Endocrine therapy; Estrogen receptor; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：473 / 483
页数：10
相关论文
共 50 条
  • [1] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Takahashi, Yuko
    Terata, Kaori
    Kida, Kumiko
    Sagara, Yasuaki
    Ueno, Takayuki
    Anan, Keisei
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Naito, Yoichi
    Hara, Fumikata
    Shien, Tadahiko
    Iwata, Hiroji
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (03) : 473 - 483
  • [2] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
    Takahashi, Yuko
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Terata, Kaori
    Sagara, Yasuaki
    Naito, Yoichi
    Kida, Kumiko
    Ueno, Takayuki
    Anan, Keisei
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Hara, Fumikata
    Shien, Tadahiko
    Iwata, Hiroji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
    Ali, Sanji
    Hendry, Jace
    Le, Duc
    Mondal, Prosanta K.
    Sami, Amer
    Chalchal, Haji
    Haider, Kamal
    Ahmed, Osama
    El-Gayed, Ali
    Wright, Philip
    Pauls, Mehrnoosh
    Johnson, Kate
    Ahmed, Shahid
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
    Sanji Ali
    Jace Hendry
    Duc Le
    Prosanta K. Mondal
    Amer Sami
    Haji Chalchal
    Kamal Haider
    Osama Ahmed
    Ali El-Gayed
    Philip Wright
    Mehrnoosh Pauls
    Kate Johnson
    Shahid Ahmed
    [J]. Scientific Reports, 12
  • [5] Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas
    Rodrigues, M. J.
    Albiges-Sauvin, L.
    Wassermann, J.
    Cottu, P. H.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (11) : 2530 - 2530
  • [6] Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
    Kelly, C. M.
    Pritchard, K. I.
    Trudeau, M.
    Andreopoulou, E.
    Hess, K.
    Pusztai, L.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (11) : 2387 - 2393
  • [7] Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors
    Rakkhit, R.
    Broglio, K.
    Peintinger, F.
    Cardoso, F.
    Hanrahan, E. O.
    Litton, J. K.
    Sahin, A.
    Larsimont, D.
    Meric-Bernstam, F.
    Buchholz, T. A.
    Valero, V.
    Theriault, R. L.
    Piccart, M.
    Ravdin, P.
    Hortobagyi, G. N.
    Gonzalez-Angulo, A. M.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 98S - 98S
  • [8] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [9] Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study
    Hendry, J.
    Ali, S.
    Ahmed, O.
    Chalchal, H.
    El-Gayed, A.
    Haider, K.
    Iqbal, N.
    Johnson, K.
    Le, D.
    Maas, B.
    Manna, M.
    Pauls, M.
    Salim, M.
    Sami, A.
    Wright, P.
    Younis, M.
    Ahmed, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S45 - S46
  • [10] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Yayoi Adachi
    Isao Oze
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Haruru Kotani
    Ayumi Kataoka
    Kayoko Sugino
    Nanae Horisawa
    Yuri Ozaki
    Yuka Endo
    Kazuki Nozawa
    Daiki Takatsuka
    Hiroji Iwata
    [J]. Breast Cancer, 2021, 28 : 1087 - 1095
12345